BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 4831456)

  • 1. [Effects of additional medication of Amantadine sulfate in L-dopa-pretreated patients with Parkinson's syndrome (author's transl)].
    Schneider E; Fischer PA; Jacobi P
    Med Klin; 1974 Mar; 69(13):541-5. PubMed ID: 4831456
    [No Abstract]   [Full Text] [Related]  

  • 2. [L-dopa therapy of Parkinson's syndrome. Comparison of pure L-dopa and the combination preparation L-dopa and decarboxylase inhibitor].
    Görlich J; Markus E
    Dtsch Med Wochenschr; 1972 Aug; 97(34):1246-8. PubMed ID: 5048316
    [No Abstract]   [Full Text] [Related]  

  • 3. L-dopa and amantadine hydrochloride in Parkinson's disease.
    Parkes JD; Zilkha KJ; Knill-Jones RP; Clements PJ; Baxter R
    Int Z Klin Pharmakol Ther Toxikol; 1971 Apr; 4(3):356-60. PubMed ID: 4931417
    [No Abstract]   [Full Text] [Related]  

  • 4. [Results of two new drugs in Parkinson's disease: L-dopa and amantadine].
    Sigwald J; Raymondeaud C; Piot C
    Rev Neurol (Paris); 1970 Feb; 122(2):145-8. PubMed ID: 4931718
    [No Abstract]   [Full Text] [Related]  

  • 5. [Therapy of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor (Ro 4-4602). Course in 71 patients].
    Ferel D
    Schweiz Med Wochenschr; 1972 Jan; 102(3):88-94. PubMed ID: 4551909
    [No Abstract]   [Full Text] [Related]  

  • 6. [Cardiovascular effects of L-dopa and decarboxylase inhibitor on patients with Parkinson's disease].
    Desjacques P; Moret P; Gauthier G
    Schweiz Med Wochenschr; 1973 Dec; 103(50):1783-5. PubMed ID: 4129257
    [No Abstract]   [Full Text] [Related]  

  • 7. [Treatment of Parkinson's syndrome with L-dopa and its methylated derivatives: 3-OMD and 4-OMD associated with a decarboxylase inhibitor. Clinical and biochemical study].
    Tissot R; Bartholini G; Constantinidis J; Eisenring JJ; Geissbühler F; Yanniotis G; de Ajuriaguerra J
    Schweiz Med Wochenschr; 1973 Oct; 103(42):1466-74. PubMed ID: 4750149
    [No Abstract]   [Full Text] [Related]  

  • 8. [Medical treatment of Parkinson's disease].
    Castaigne P; Rondot P; Ribadeau-Dumas JL
    Ann Med Interne (Paris); 1972 Apr; 123(4):357-64. PubMed ID: 5077040
    [No Abstract]   [Full Text] [Related]  

  • 9. Amantadine HCL (Symmetrel) and its relation to Levo-Dopa in the treatment of Parkinson's disease.
    Schwab RS; England AC
    Trans Am Neurol Assoc; 1969; 94():85-90. PubMed ID: 4907453
    [No Abstract]   [Full Text] [Related]  

  • 10. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease.
    Andrews CJ; Somerville B
    Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384
    [No Abstract]   [Full Text] [Related]  

  • 11. [Combination therapy of Parkinson's syndrome using L-dopa and a decarboxylase inhibitor].
    Fischer PA; Schneider E; Jacobi P; Maxion H
    Med Welt; 1973 Nov; 24(45):1742-6. PubMed ID: 4768206
    [No Abstract]   [Full Text] [Related]  

  • 12. [Amantadine hydrochloride in the treatment of Parkinson's syndrome].
    De la Herrán J; Figuerido JA
    Rev Esp Otoneurooftalmol Neurocir; 1971; 29(167):45-9. PubMed ID: 5091472
    [No Abstract]   [Full Text] [Related]  

  • 13. [Problematic long-term therapy of Parkinson's syndrome using amantadine salts].
    Diehl LW
    Med Welt; 1975 Nov; 26(48):2188-91. PubMed ID: 813085
    [No Abstract]   [Full Text] [Related]  

  • 14. [Accomplishment of the treatment and evaluation of treatment alternatives in parkinsonism].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2119. PubMed ID: 4773985
    [No Abstract]   [Full Text] [Related]  

  • 15. L-dopa treatment of parkinsonism. Clinical observations on the use of amantadine hydrochloride.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1971 Aug; 26(8):61-70. PubMed ID: 5096462
    [No Abstract]   [Full Text] [Related]  

  • 16. [Experiences in the treatment of Parkinson's disease with a combination drug: L-dopa plus decarboxylase inhibitor (Ro 8-0576)].
    Steinhäusl H
    Wien Med Wochenschr; 1973 Jun; 123(26):433-5. PubMed ID: 4578743
    [No Abstract]   [Full Text] [Related]  

  • 17. [Present-day treatment of parkinsonism in the aged].
    Siegfried J
    Schweiz Rundsch Med Prax; 1973 Oct; 62(40):1202-3. PubMed ID: 4754539
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical trial of the therapeutic effect of Amantadine-HCL in Parkinson's Disease].
    Hacohen H; Gurtner B
    Schweiz Med Wochenschr; 1972 Apr; 102(16):583-6. PubMed ID: 5019377
    [No Abstract]   [Full Text] [Related]  

  • 19. [Therapy of Parkinsonism using L-dopa in combination with a decarboxylase inhibitor].
    Stammler A; Vielhaber K
    Fortschr Neurol Psychiatr Grenzgeb; 1972 Oct; 40(10):564-8. PubMed ID: 4565521
    [No Abstract]   [Full Text] [Related]  

  • 20. [Treatment of Parkinson's syndrome with L-dopa and a decarboxylase inhibitor].
    Lombardo L; de la Garza R; Ivan-Reynoso G
    Arch Invest Med (Mex); 1974; 5(2):105-16. PubMed ID: 4433198
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.